Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2022-08-30 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Evusheld approved for COVID-19 in Japan
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 6154X' and is dated '30 August 2022'. It details a specific corporate event: the approval of AstraZeneca's Evusheld in Japan for COVID-19 prevention and treatment. The structure, including the RNS header, the immediate announcement of a material event (drug approval), and the closing signature by the Company Secretary, strongly indicates this is a regulatory news service announcement. Since it is a specific, time-sensitive announcement that doesn't fit the definitions for 10-K, ER, or IR, the most appropriate classification is RNS (Regulatory Filings), which serves as the general category for such market disclosures not covered by more specific codes.
2022-08-30 English
FARXIGA REDUCED RISK OF CV DEATH OR WORSENING HF
Foreign Filer Report
2022-08-30 English
FARXIGA SHOWS CV MORTALITY BENEFIT ACROSS EF RANGE
Foreign Filer Report
2022-08-30 English
Farxiga shows CV mortality benefit across EF range
Regulatory Filings Classification · 98% confidence The document is identified by the header 'RNS Number : 4513X' and contains a date stamp '30 August 2022 07:01 BST'. The content details new clinical trial results for the drug Farxiga (dapagliflozin) related to heart failure, including statistical outcomes and quotes from company executives and researchers. The document concludes with standard disclaimers and contact information typical of a regulatory news service release, specifically mentioning 'RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure strongly indicates a general regulatory announcement rather than a comprehensive financial report (like 10-K or IR) or a specific shareholder communication (like DEF 14A). Since it is a broad regulatory announcement that doesn't fit the more specific categories (like DIV, ER, or CT), the appropriate fallback is Regulatory Filings (RNS). The document length (12,910 chars) is substantial, suggesting it is the primary content, not just a brief announcement of a report.
2022-08-30 English
Farxiga reduced risk of CV death or worsening HF
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 4512X' and is dated August 30, 2022. It details the positive results of the DELIVER Phase III trial for AstraZeneca's drug Farxiga, including presentation at a medical congress and simultaneous publication in the New England Journal of Medicine. This is a press release announcing significant clinical trial data and regulatory/medical milestones. Since it is a formal announcement distributed via the RNS system (London Stock Exchange's news service) and contains detailed scientific/clinical updates rather than just financial highlights (ER) or a full annual report (10-K), it fits best under the general 'Regulatory Filings' category (RNS) as a significant corporate/clinical update distributed through the official channel, or potentially an Investor Presentation (IP) if it were structured as slides, but the format strongly suggests a regulatory news service announcement.
2022-08-30 English
ULTOMIRIS APPROVED IN JAPAN FOR GMG
Foreign Filer Report
2022-08-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.